. Author manuscript; available in PMC: 2014 May 1.

Published in final edited form as: J Subst Abuse Treat. 2012 Dec 3;44(5):473–480. doi: 10.1016/j.jsat.2012.10.004

Table 4.

Conditions under which agonist treatment is available (N=90)

	Methadone	Buprenorphine	Any Agonist
	N (%)^*	N (%)^*	N (%)^*
Tapered detox for participants currently receiving methadone or buprenorphine	26 (28)	32 (33)	38 (40)
For all participants who are currently receiving methadone or buprenorphine.	20 (22)	29 (31)	36 (40)
For induction and maintenance for participants who have been using illicit opioids.	16 (17)	27 (30)	31 (34)
For pregnant participants currently receiving methadone or buprenorphine	16 (19)	22 (24)	25 (28)
For pregnant participants who have been using illicit opioids.	13 (14)	20 (22)	23 (26)
Other circumstances	3 (2)	3 (2)	3 (2)
Not permitted under any circumstances	42 (45)	38 (43)	45 (50)

all percentages weighted to account for over/underrepresentation of courts in rural, suburban, and urban regions.